Evaluation of 3-Month Data for the Use of Erenumab for Chronic Migraine in Glasgow
May 2022
in “
Journal of Neurology Neurosurgery & Psychiatry
”
New to Botox? There is a guide in the encyclopedia. Read the guide → Studysummary In this study, 81% of patients with chronic migraine in Glasgow continued using erenumab for significant headache reduction at three months, suggesting a high response rate.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer